SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression

Molecular Cell

Volumn 59, Issue 6, 2015, Pages 917-930

  Gan, Wenjian ^a   Dai, Xiangpeng ^a   Lunardi, Andrea ^a   Li, Zhen ^b   Inuzuka, Hiroyuki ^a   Liu, Pengda ^a   Varmeh, Shoreh ^c   Zhang, Jinfang ^a   Cheng, Liang ^d   Sun, Yin ^b,e   Asara, John M ^a   Beck, Andrew H ^a   Huang, Jiaoti ^b   Pandolfi, Pier Paolo ^a   Wei, Wenyi ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; ONCOPROTEIN; TRANSCRIPTION FACTOR ERG; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE SPOP; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CUL3 PROTEIN, HUMAN; CULLIN; ERG PROTEIN, HUMAN; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SPOP PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENETIC ASSOCIATION; GENETIC STABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOLECULAR PATHOLOGY; MUTANT; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SOMATIC MUTATION; UBIQUITINATION; WESTERN BLOTTING; AMINO ACID SEQUENCE; CELL MOTION; DISEASE COURSE; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; PROTEIN DOMAIN; TUMOR CELL LINE; TUMOR INVASION;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; CELL MOVEMENT; CULLIN PROTEINS; DISEASE PROGRESSION; ETOPOSIDE; HEK293 CELLS; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PROSTATIC NEOPLASMS; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOLYSIS; REPRESSOR PROTEINS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

EID: 84941752941     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2015.07.026     Document Type: Article

References (41)

1. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S., Palmiter R.D., Brinster R.L. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538.
2. Alsheich-Bartok O., Haupt S., Alkalay-Snir I., Saito S., Appella E., Haupt Y. PML enhances the regulation of p53 by CK1 in response to DNA damage. Oncogene 2008, 27:3653-3661.
3. An J., Wang C., Deng Y., Yu L., Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014, 6:657-669.
4. An J., Ren S., Murphy S.J., Dalangood S., Chang C., Pang X., Cui Y., Wang L., Pan Y., Zhang X., et al. Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Mol Cell 2015, 59:904-916. this issue.
5. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., White T.A., Stojanov P., Van Allen E., Stransky N., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689.
6. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., Sboner A., Esgueva R., Pflueger D., Sougnez C., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
7. Cardozo T., Pagano M. The SCF ubiquitin ligase: insights into a molecular machine. Nat. Rev. Mol. Cell Biol. 2004, 5:739-751.
8. Carver B.S., Tran J., Chen Z., Carracedo-Perez A., Alimonti A., Nardella C., Gopalan A., Scardino P.T., Cordon-Cardo C., Gerald W., et al. ETS rearrangements and prostate cancer initiation. Nature 2009, 457. E1; discussion E2-3.
9. Carver B.S., Tran J., Gopalan A., Chen Z., Shaikh S., Carracedo A., Alimonti A., Nardella C., Varmeh S., Scardino P.T., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat. Genet. 2009, 41:619-624.
10. Cerami E., Gao J., Dogrusoz U., Gross B.E., Sumer S.O., Aksoy B.A., Jacobsen A., Byrne C.J., Heuer M.L., Larsson E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012, 2:401-404.
11. Clark J.P., Cooper C.S. ETS gene fusions in prostate cancer. Nat. Rev. Urol. 2009, 6:429-439.
12. Clark J., Merson S., Jhavar S., Flohr P., Edwards S., Foster C.S., Eeles R., Martin F.L., Phillips D.H., Crundwell M., et al. Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene 2007, 26:2667-2673.
13. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
14. Geng C., He B., Xu L., Barbieri C.E., Eedunuri V.K., Chew S.A., Zimmermann M., Bond R., Shou J., Li C., et al. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc. Natl. Acad. Sci. USA 2013, 110:6997-7002.
15. Geng C., Rajapakshe K., Shah S.S., Shou J., Eedunuri V.K., Foley C., Fiskus W., Rajendran M., Chew S.A., Zimmermann M., et al. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014, 74:5631-5643.
16. Genschik P., Sumara I., Lechner E. The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications. EMBO J. 2013, 32:2307-2320.
17. Huang J., Yao J.L., Zhang L., Bourne P.A., Quinn A.M., di Sant'Agnese P.A., Reeder J.E. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am. J. Pathol. 2005, 166:1807-1815.
18. Inuzuka H., Tseng A., Gao D., Zhai B., Zhang Q., Shaik S., Wan L., Ang X.L., Mock C., Yin H., et al. Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 2010, 18:147-159.
19. King J.C., Xu J., Wongvipat J., Hieronymus H., Carver B.S., Leung D.H., Taylor B.S., Sander C., Cardiff R.D., Couto S.S., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat. Genet. 2009, 41:524-526.
20. Kumar-Sinha C., Tomlins S.A., Chinnaiyan A.M. Recurrent gene fusions in prostate cancer. Nat. Rev. Cancer 2008, 8:497-511.
21. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947.
22. Li C., Ao J., Fu J., Lee D.F., Xu J., Lonard D., O'Malley B.W. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 2011, 30:4350-4364.
23. Lindberg J., Klevebring D., Liu W., Neiman M., Xu J., Wiklund P., Wiklund F., Mills I.G., Egevad L., Grönberg H. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur. Urol. 2013, 63:347-353.
24. Park K., Tomlins S.A., Mudaliar K.M., Chiu Y.L., Esgueva R., Mehra R., Suleman K., Varambally S., Brenner J.C., MacDonald T., et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia 2010, 12:590-598.
25. Perner S., Mosquera J.M., Demichelis F., Hofer M.D., Paris P.L., Simko J., Collins C., Bismar T.A., Chinnaiyan A.M., De Marzo A.M., Rubin M.A. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am. J. Surg. Pathol. 2007, 31:882-888.
26. Petroski M.D., Deshaies R.J. Function and regulation of cullin-RING ubiquitin ligases. Nat. Rev. Mol. Cell Biol. 2005, 6:9-20.
27. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer 2005, 5:172-183.
28. Rubin M.A., Maher C.A., Chinnaiyan A.M. Common gene rearrangements in prostate cancer. J. Clin. Oncol. 2011, 29:3659-3668.
29. Schelling L.A., Williamson S.R., Zhang S., Yao J.L., Wang M., Huang J., Montironi R., Lopez-Beltran A., Emerson R.E., Idrees M.T., et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum. Pathol. 2013, 44:2227-2233.
30. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J. Clin. 2013, 63:11-30.
31. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Théodore C., James N.D., Turesson I., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004, 351:1502-1512. TAX 327 Investigators.
32. Thalmann G.N., Sikes R.A., Devoll R.E., Kiefer J.A., Markwalder R., Klima I., Farach-Carson C.M., Studer U.E., Chung L.W. Osteopontin: possible role in prostate cancer progression. Clin. Cancer Res. 1999, 5:2271-2277.
33. Theurillat J.P., Udeshi N.D., Errington W.J., Svinkina T., Baca S.C., Pop M., Wild P.J., Blattner M., Groner A.C., Rubin M.A., et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science 2014, 346:85-89.
34. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
35. Tomlins S.A., Laxman B., Dhanasekaran S.M., Helgeson B.E., Cao X., Morris D.S., Menon A., Jing X., Cao Q., Han B., et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007, 448:595-599.
36. Tomlins S.A., Laxman B., Varambally S., Cao X., Yu J., Helgeson B.E., Cao Q., Prensner J.R., Rubin M.A., Shah R.B., et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008, 10:177-188.
37. Vitari A.C., Leong K.G., Newton K., Yee C., O'Rourke K., Liu J., Phu L., Vij R., Ferrando R., Couto S.S., et al. COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature 2011, 474:403-406.
38. Wang Z., Inuzuka H., Zhong J., Fukushima H., Wan L., Liu P., Wei W. DNA damage-induced activation of ATM promotes β-TRCP-mediated Mdm2 ubiquitination and destruction. Oncotarget 2012, 3:1026-1035.
39. Wang S., Kollipara R.K., Srivastava N., Li R., Ravindranathan P., Hernandez E., Freeman E., Humphries C.G., Kapur P., Lotan Y., et al. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc. Natl. Acad. Sci. USA 2014, 111:4251-4256.
40. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat. Rev. Cancer 2008, 8:83-93.
41. Zhuang M., Calabrese M.F., Liu J., Waddell M.B., Nourse A., Hammel M., Miller D.J., Walden H., Duda D.M., Seyedin S.N., et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol. Cell 2009, 36:39-50.